Estudio sobre susceptibilidad de cáncer de vejiga y polimorfismos genéticos de XPC, XPG y CYP en fumadores y no fumadores

Wen, Hao; Feng, Chenchen; Fang, Zhaoxi; Xia, Guowei; Jiang, Haowen; Xu, Gang; Huang, Xiaokun; Ding, Qiang

doi:10.1016/j.acuro.2012.04.007

Cited by 13 publications

(7 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the exclusion criteria, 14 publications were excluded including 4 publications containing overlapping data [17–20], 2 for not presenting sufficient data for calculating OR and 95% CI [21,22], 5 were not case-control studies [23–27], 2 were meta-analysis [28,29] and one was a review [30]. Manual search of references cited in the eligible studies did not reveal any additional article As a result, a total of 25 relevant studies including 22 English articles [2,6,10,31–49], 2 Chinese papers (one was a dissertation of postgraduate student) [50,51], and one Spanish study [52] met the inclusion criteria for the meta-analysis. Among them, one of the eligible studies contained data on two different ethnic groups (African and Caucasian) [10], and we treated it independently.…”

Section: Resultsmentioning

confidence: 99%

DNA Repair Gene XRCC1 Polymorphisms, Smoking, and Bladder Cancer Risk: A Meta-Analysis

Peng

Chen

et al. 2013

PLoS ONE

View full text Add to dashboard Cite

Background and ObjectiveThe X-ray repair cross-complementing group 1 (XRCC1) protein plays a crucial role in base excision repair (BER) pathway by acting as a scaffold for other BER enzymes. Variants in the XRCC1 gene might alter protein structure or function or create alternatively spliced proteins which may influence BER efficiency and hence affect individual susceptibility to bladder cancer. Recent epidemiological studies have shown inconsistent associations between these polymorphisms and bladder cancer. To clarify the situation, a comprehensive meta-analysis of all available studies was performed in this study.MethodsPubMed, EMBASE, and Chinese Biomedical Literature database (CBM) databases have been systematically searched to identify all relevant studies for the period up to February 2013. Data were abstracted independently by two reviewers and Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Subgroup analyses were performed mainly by ethnicity and smoking status.ResultsA total of 26 case-control studies, including 24 studies for R399Q polymorphism, 15 studies for R194W polymorphism, and 7 studies for R280H polymorphism met the inclusion criteria and were selected. With respect to R399Q polymorphism, significantly decreased bladder cancer risk was found among smokers (AA vs. GG: OR=0.693, 95%CI= 0.515-0.932, P=0.015 and recessive model AA vs. GA+GG: OR=0.680, 95%CI= 0.515-0.898, P=0.007, respectively). With respect to R194W and R280H polymorphism, significantly increased bladder cancer risk were observed among Asians (TT+CT vs. CC:OR = 1.327, 95% CI 1.086-1.622, P=0.006 for R194W, and AA+GA vs. GG: OR=2.094, 95% CI 1.211–3.621, P=0.008 for R280H, respectively).ConclusionsThis meta-analysis suggests that the XRCC1 R399Q polymorphism may play a protective role against bladder cancer among smokers. However, the XRCC1 R194W and R280H polymorphisms were both associated with increased bladder cancer risk among Asians. Further studies with larger sample sizes are needed to validate our finds.

show abstract

Section: Resultsmentioning

confidence: 99%

DNA Repair Gene XRCC1 Polymorphisms, Smoking, and Bladder Cancer Risk: A Meta-Analysis

Peng

Chen

et al. 2013

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Table 1 showed the characteristics of all the eligible studies and genotype frequency distributions of twelve polymorphisms in five XRCC genes ( XRCC1 -rs915927, XRCC1 -rs25489, XRCC1 -rs25487, XRCC1 -rs1799782, XRCC1 -rs3213245, XRCC2 -rs3218536, XRCC3 -rs1799796, XRCC3 -rs861539, XRCC4 -rs6869366, XRCC4 -rs28360071, XRCC4 -rs1805377, XRCC7 -rs7003908) included in current meta-analysis (Agalliu et al, 2010, Andrew et al, 2015, Andrew et al, 2007, Andrew et al, 2006, Arizono et al, 2008, Berhane et al, 2012, Broberg et al, 2005, Chang et al, 2009, Lan et al, 2006, Lavender et al, 2010, Chang et al, 2008, Dhillon et al, 2009, Figueroa et al, 2007a, Figueroa et al, 2007b, Fontana et al, 2008, Gangwar et al, 2009, Hamano et al, 2008, Hirata et al, 2006, Hirata et al, 2007, Huang et al, 2007, Abe et al, 2011, Mittal et al, 2008, Narter et al, 2009, Nowacka-Zawisza et al, 2015, Ramaniuk et al, 2014, Ritchey et al, 2005, Rybicki et al, 2004, Sak et al, 2007, Sanyal et al, 2004, Shen et al, 2003, Stern et al, 2002, Stern et al, 2001, Van Gils et al, 2002, Wang et al, 2010, Wang et al, 2008, Wen et al, 2009, Wen et al, 2013, Wu et al, 2006, Xu et al, 2007, Zhi et al, 2012, Hao et al, 2008, Zhou et al, 2012, Zhu et al, 2014, Zhu et al, 2012, Kelsey et al, 2004, Kuasne et al, 2011, Luedeke et al, 2009, Mandal et al, 2010, Mandal et al, 2011, Matullo, 2005, Matullo et al, 2006, Matullo et al, 2001, Mittal et al, 2012a, Mittal et al, 2012b). The study selection processes were presented in Supplementary Figs.…”

Section: Resultsmentioning

confidence: 99%

Association Between Twelve Polymorphisms in Five X-ray Repair Cross-complementing Genes and the Risk of Urological Neoplasms: A Systematic Review and Meta-Analysis

Zhang¹,

Li²,

Hao³

et al. 2017

EBioMedicine

View full text Add to dashboard Cite

Polymorphisms in X-ray repair cross-complementing (XRCC) genes have been implicated in altering the risk of various urological cancers. However, the results of reported studies are controversial. To ascertain whether polymorphisms in XRCC genes are associated with the risk of urological neoplasms, we conducted present updated meta-analysis and systematic review. Summary odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were used to estimate the association. Finally, 54 publications comprising 129 case-control studies for twelve polymorphisms in five XRCC genes were enrolled. We identified that XRCC1-rs25489 polymorphism was associated with an increased risk of urological neoplasms in heterozygote and dominant models. Moreover, in the subgroup analysis by cancer type, we found that XRCC1-rs25489 polymorphism was associated with an increased risk of bladder cancer (BC) in heterozygote model. Although overall analyses suggested a null result for XRCC1-rs25487 polymorphism, in the stratified analysis by ethnicity, an increased risk of urological neoplasms for Asians in allelic and homozygote models was identified. While for other polymorphisms in XRCC genes, no significant association was uncovered. To sum up, our results indicated that XRCC1-rs25489 polymorphism is a risk factor for urological neoplasms, particularly for BC. Further studies with large sample size are needed to validate these findings.

show abstract

“…The results indicated that sample size (recessive model: P = 0.038) but not cancer type (dominant model: P = 0.782; recessive model: P = 0.208; His/His versus Asp/Asp: P = 0.336; Asp/His versus Asp/Asp: P = 0.825; additive model: P = 0.556), ethnicity (dominant model: P = 0.298; recessive model: P = 0.119; His/His versus Asp/Asp: P = 0.066; Asp/His versus Asp/Asp: P = 0.449; additive model: P = 0.241), source of controls (dominant model: P = 0.433; recessive model: P = 0.821; His/His versus Asp/Asp: P = 0.634; Asp/His versus Asp/Asp: P = 0.358; additive model: P = 0.429), and HWE (dominant model: P = 0.126; recessive model: P = 0.660; His/His versus Asp/Asp: P = 0.272; Asp/His versus Asp/Asp: P = 0.123; additive model: P = 0.217) contributed to substantial heterogeneity among the meta-analysis. Examining genotype frequencies in the controls, significant deviation from HWE was detected in the eight studies [10], [26], [43], [44], [45], [53], [80], [81]. When these studies were excluded, the results were changed among overall cancer (dominant model: OR = 1.03, 95% CI = 0.99–1.08), Asians of lung cancer (dominant model: OR = 1.15, 95% CI = 0.95–1.41; His/His versus Asp/Asp: OR = 1.20, 95% CI = 0.92–1.55; additive model: OR = 1.10, 95% CI = 0.96–1.25), and hospital-based studies of other cancer (recessive model: OR = 1.23, 95% CI = 1.02–1.49; His/His versus Asp/Asp: OR = 1.20, 95% CI = 0.97–1.48), as shown in Table 5 .…”

Section: Resultsmentioning

confidence: 99%

Association between the XPG Asp1104His and XPF Arg415Gln Polymorphisms and Risk of Cancer: A Meta-Analysis

Liu

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

BackgroudThe XPG (xeroderma pigmentosum type G) Asp1104His and XPF (xeroderma pigmentosum type F) Arg415Gln polymorphisms had been implicated in cancer susceptibility. The previous published data on the association between XPG Asp1104His and XPF Arg415Gln polymorphisms and cancer risk remained controversial.Methodology/Principal FindingsTo derive a more precise estimation of the association between the XPG Asp1104His and XPF Arg415Gln polymorphisms and overall cancer risk, we performed a meta-analysis to investigate the association between cancer susceptibility and XPG Asp1104His (32,162 cases and 39,858 controls from 66 studies) and XPF Arg415Gln polymorphisms (17,864 cases and 20,578 controls from 32 studies) in different inheritance models. We used odds ratios with 95% confidence intervals to assess the strength of the association. Overall, significantly elevated cancer risk was found when all studies were pooled into the meta-analysis of XPG Asp1104His (dominant model: OR = 1.05, 95% CI = 1.00–1.10; Asp/His vs. Asp/Asp: OR = 1.06, 95% CI = 1.01–1.11). In the further stratified and sensitivity analyses, significantly decreased lung cancer risk was found for XPF Arg415Gln (dominant model: OR = 0.82, 95% CI = 0.71–0.96; Arg/Gln versus Arg/Arg: OR = 0.83, 95% CI = 0.71–0.97; additive model: OR = 0.83, 95% CI = 0.72–0.95) and significantly increased other cancer risk was found among hospital-based studies for XPG Asp1104His (dominant model: OR = 1.23, 95% CI = 1.02–1.49).Conclusions/SignificanceIn summary, this meta-analysis suggests that XPF Arg415Gln polymorphism may be associated with decreased lung cancer risk and XPG Asp1104His may be a low-penetrant risk factor in some cancers development. And larger scale primary studies are required to further evaluate the interaction of XPG Asp1104His and XPF Arg415Gln polymorphisms and cancer risk in specific populations.

show abstract

Estudio sobre susceptibilidad de cáncer de vejiga y polimorfismos genéticos de XPC, XPG y CYP en fumadores y no fumadores

Cited by 13 publications

References 15 publications

DNA Repair Gene XRCC1 Polymorphisms, Smoking, and Bladder Cancer Risk: A Meta-Analysis

DNA Repair Gene XRCC1 Polymorphisms, Smoking, and Bladder Cancer Risk: A Meta-Analysis

Association Between Twelve Polymorphisms in Five X-ray Repair Cross-complementing Genes and the Risk of Urological Neoplasms: A Systematic Review and Meta-Analysis

Association between the XPG Asp1104His and XPF Arg415Gln Polymorphisms and Risk of Cancer: A Meta-Analysis

Contact Info

Product

Resources

About